Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Website URL
Similar Companies1000
Immutep
Immutep is a global biotechnology company developing immunotherapeutic products for the treatment of cancer and autoimmune diseases.
Sector
Subsector
Location
total rounds
total raised
Immunovo
Immunovo is a Dutch biotechnology company focused on developing immunotherapeutic drugs.
Sector
Subsector
Keywords
Location
total rounds
OSE Immunotherapeutics
OSE Immunotherapeutics is a biotech company developing innovative treatments for cancer and inflammatory diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
MacroGenics
MacroGenics is a biotech company that develops immunotherapeutics for autoimmune disorders, cancer, and infectious diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds2
Number of Funding Rounds
Money Raised
Their latest funding was raised on 09.07.2020. Their latest investor National Institute of Allergy and Infectious Diseases. Their latest round Series A
Two Bear Capital
Two Bear Capital invests in early-stage companies with disruptive innovations in biotech, AI, and cybersecurity.
Sector
Subsector
Location
count Of Investments
National Institute of Allergy and Infectious Diseases
NIAID conducts research to prevent and treat infectious and allergic diseases.
Sector
Subsector
Location
count Of Investments
count Of Exists
National Institute of Allergy and Infectious Diseases
National Institute of Allergy and Infectious is a medical research agency that supports basic and applied research for allergic diseases.
count Of Investments
count Of Exists
Co-Investors
Investors3
Number of lead investors
Number of investors
National Institute of Allergy and Infectious Diseases
NIAID conducts research to prevent and treat infectious and allergic diseases.
Sector
Subsector
Location
count Of Investments
count Of Exists
National Institute of Allergy and Infectious Diseases
National Institute of Allergy and Infectious is a medical research agency that supports basic and applied research for allergic diseases.
count Of Investments
count Of Exists
Two Bear Capital
Two Bear Capital invests in early-stage companies with disruptive innovations in biotech, AI, and cybersecurity.
Sector
Subsector
Location
count Of Investments
Michael Goguen
Michael Goguen was previously a venture capitalist at Sequoia Capital, focusing on energy, internet and technology investments. Michael currently sits on the board of Clean Cell, Clickatell Inc, Infoblox, Litepoint, OpenDNS, LogLogic, Quantenna Communications, R2 Semiconductors, Synapsense, Think Finance and Tula. Prior to joining Sequoia Capital in 1996, Michael spent 10 years in various engineering, research, and product management roles at DEC, SynOptics and Centillion, and was a director of Engineering at Bay Networks (NT). Michael was also a Technical Chairman of the ATM Forum.
current job
organization founded
People
Founders4
Kendal Ryter
Kendal Ryter is a VP Product Development at Inimmune Corp. He attended Montana State University-Bozeman.
current job
organization founded
Kendal Ryter
Jay T. Evans
Evans Jay is the President and CEO at Inimmune Corporation.He attended Oregon State University.
current job
organization founded
Jay T. Evans
David J. Burkhart
Dr. David Burkhart is the Chief Operating Officer and Co-Founder of Inimmune, while also overseeing the formulation science R&D team. Dr. Burkhart was an investigator with GlaxoSmithKline for nearly 8 years leading the formulation R&D team where he demonstrated a knack for innovation and project/team management which led to his promotion from his starting role as a Principal Scientist. Prior to his work with GSK, Dr. Burkhart was a Senior Scientist with the CMO Hollister-Stier labs in Spokane, Washington for two years where he gained invaluable experience in cGMP analytical and manufacturing. He has over 10 years of experience in the biotechnology and pharmaceutical industries with experience in project management, leadership, business development, and licensing with over 13 years experience in medicinal and analytical chemistry, formulation and drug delivery. David earned his Ph.D. in organic chemistry in 2002 from the University of Idaho and conducted research in oncology as a postdoctoral scientist at the University of Colorado, Boulder until 2005.
current job
organization founded
David J. Burkhart
Helene Bazin-Lee
Dr. Bazin-Lee is VP, Early Discovery and Co-Founder of Inimmune, serving as head of early discovery research programs. She has over 17 years of experience in the biotech and pharmaceutical industries including 14 years with Corixa/GlaxoSmithKline developing new synthetic immunomodulators and vaccine adjuvants, managing medicinal chemistry efforts and new adjuvant discovery projects. Dr. Bazin-Lee earned an M.Sc. in Chemical Engineering at the ENSCCF (France) and received her Ph.D. in Organic Chemistry from the University of Lyon I (France). She then completed a postdoctoral fellowship at the University of Iowa, focusing on the development of new synthetic methods for the synthesis of glycosaminoglycan building blocks. Dr. Bazin-Lee is a co-inventor on 15 patents.
current job
organization founded
Helene Bazin-Lee
Employee Profiles4
Helene Bazin-Lee
Co-Founder & Vice President Early Discovery
David J. Burkhart
Co-Founder & Chief Operating Officer
Activity
Recent News3
The graph reveals the ratio (%) of positive news articles in a chosen time range